medigraphic.com

2014, Number 2

<< Back Next >>

Rev Esp Cienc Salud 2014; 17 (2)

Cell cycle: regulation mechanism

Lagunas CMC, Valle MA, Soto CI

Language: Spanish
References: 52
Page: 98-107
PDF size: 514.58 Kb.


ABSTRACT

The cell cycle is a process in which a cell grows and divides to create a copy of itself, allowing the cells to grow and replace as they wear out. In animals, the cycle of a normal cell takes about 24 hours from the beginning to the end for most cell types, although some, such as skin cells, or tumor cells, are constantly undergoing this cycle, while others can divide rarely or do not divide at all.
The sequence of events that occur when a cell is stimulated to grow and divide is the cell cycle. It starts with resting cells (G0) that have to be stimulated by growth factors to enter the cell cycle, which begins with the first period of growth (G1) to be prepared for a period of DNA synthesis (S-phase). Towards the end of G1, there is a restriction point (R), in which DNA should be repaired if damaged, if not the cycle goes on. Once the cell has doubled its chromosomes, the cell goes into a second period of growth (G2), as it prepares to divide into two daughter cells during the mitosis (M phase). This phase M is separated into a series of discrete steps beginning with prophase and then pass through the metaphase, anaphase, telophase and, finally, the process of cytokinesis, then the cell divides into two equal.


REFERENCES

  1. Coudreuse D and Nurse P. Driving the cell cycle with a minimal CDK control network. Nature. 2010; 468 (23):1074-1080.

  2. Young TK and Min Z. Aberrant Cell Cycle Regulation in Cervical Carcinoma Yonsei Medical Journal. 2005; 46(5):597–613.

  3. Sherr CJ.. Gl Phase Progression: Cycling on Cue. Cell. 1994; 79(4):551-555.

  4. Suárez N, Gil CG, Marco AM, Ortega A, Trinidad P. Tratado de otorrinolaringología y cirugía de cabeza y cuello. Madrid. Editorial Médica Panamericana. 2007; Pp. 247.

  5. Zhou BB and Elledge SJ. . The DNA damage response: putting checkpoints in perspective. Nature. 2000; 408(6811):433-439.

  6. Kastan MB1, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316-323.

  7. Sperka T1, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nature reviews. Molecular cell biology. 2012; 13(9):579-90.

  8. Klermund, Bender K, Luke B. High Nutrient Levels and TORC1 Activity Reduce Cell Viability following Prolonged Telomere Dysfunction and Cell Cycle Arrest. Cell reports. 2014; 9(1):324-35. doi: 10.1016/j.celrep.2014.08.053.

  9. Duronio RJ and Xiong Y. Signaling pathways that control cell proliferation. Cold Spring Harbor perspectives in biology. 2013; 5(3):a008904. doi: 10.1101/cshperspect.a008904.

  10. Giacinti C and Giordano A. RB and cell cycle progression. Oncogene. 2006; 25(38):5220-5227.

  11. Neganova and Lako M. G1 to S phase cell cycle transition in somatic and embryonic stem cells. Journal of anatomy. 2008; 213(1):30-44. doi: 10.1111/j.1469-7580.2008.00931.x.

  12. Frolov MV and Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. Journal of cell science. 2004; 117(Pt 11):2173-2181.

  13. Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL. Cyclin D as a therapeutic target in cancer. Nature review in cancer. 2011;11(8): 558-572.

  14. Schulz GM, Machado DC, Jeckel, Schenk MV. Cyclin D1 expression and cervical metastases in squamous cell carcinoma of the mouth. Revista Bras otorinolaringol. 2007; 73(1):93-100.

  15. Miettinen HE, Paunu N, Rantala I, Kalimo H, Paljärvi L, Helin H, Haapasalo H. Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique. 2001; 55(1):29- 37.

  16. Wu J, Lv Q, He J, Zhang H, Mei X, Cui K, Huang N, Xie W, Xu N, Zhang Y. MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes. Cell Communication and Signaling. 2014; 12(1):66.

  17. Cho HJ and Park JH. Kaempferol Induces Cell Cycle Arrest in HT-29 Human Colon Cancer Cells. Journal of cancer prevention. 2013; 18(3):257-263.

  18. Lu X1, Jung Ji, Cho HJ, Lim DY, Lee HS, Chun HS, Kwon DY, Park JH. Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. The Journal of nutrition. 2005; 135(12):2884-90.

  19. Cao Z, Li X, Li J, Luo W, Huang C, Chen J. X-linked inhibitor of apoptosis protein (XIAP) lacking RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the E2F1/Cyclin E axis. Oncotarget. 2014; 5(16):7126-137.

  20. Little and Stewart CJS. Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. 2010; 23(4): 611-618.

  21. Zentella DA, López MR, Gómez GE, Paredes GRE y Ibarra SMJ. El ciclo celular y su regulación: La interacción entre las proteínas cinasas CDKs y la familia de las ciclinas. Revista de Educación Bioquímica. 1996; 15(1): 4-12.

  22. Besson A, Dowdy SF, and Roberts JM. CDK Inhibitors: Cell Cycle Regulators and Beyond. 2008;14(2): 159-169.

  23. Lee M, Song BJ and Kwon Y. Ethanol Mediates Cell Cycle Arrest and Apoptosis in SK-N-SH Neuroblastoma Cells. Journal of cancer prevention. 2014; 19(1):39-46.

  24. Casini T and Pelicci PG. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene. 1999;18 (21):3235-3243.

  25. Campbell Neil A, Urry L, Jane B Reece. Biología. Madrid. Médica Panamericana, 7ma edición. 2010. Pp 221.

  26. http://www.med.ufro.cl/clases_apuntes/cs_basica/bioquimica_ dr_rocha/O-CAPITULO_14-vinc-segunda-edicion.pdf consultado noviembre 2014.

  27. Quezada RMA. El ciclo celular, sus alteraciones en cáncer y como es regulado en células troncales embrionarias. Contactos. 2007; 65:5-12.

  28. Peralta-Zaragoza O, Bahena-Román M, Díaz-Benítez CE, Madrid-Marina V. Regulación del ciclo celular y desarrollo de cáncer: perspectivas terapéuticas. Salud Pública México 1997; 39(5):451-462.

  29. Fumagalli M, Rossiello F, Mondello C, d’Adda di Fagagna F. Stable Cellular Senescence Is Associated with Persistent DDR Activation. Plus one. 9(10):| e110969. doi: 10.1371/journal.pone.0110969. eCollection 2014.

  30. Hansakul P, Aree K, Tanochit S, Itharat A. Growth arrest and apoptosis via caspase activation of dioscoreanone in human nonsmall- cell lung cancer A549 cells. BioMed Central complementary and alternative medicine Complementary and alternative medicine. 2014; 14(1):413.

  31. Tang D1, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW and Ingram AJ. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem. 2002; 277(15):12710-12717.

  32. Yan Y1, Hein AL1, Etekpo A2, Burchett KM2, Lin C1, Enke CA1, Batra SK3, Cowan KH2, Ouellette MM4. Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to g-irradiation. Oncotarget. 2014; [Epub ahead of print].

  33. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. The Journal of biological chemistry. 2006; 281(35):25134- 25142.

  34. Otsuka and Ochiya. Genetic Networks Lead and Follow Tumor Development: MicroRNA Regulation of Cell Cycle and Apoptosis in the p53 Pathways. BioMed research international. 2014; 2014:749724 doi: 10.1155/2014/749724.

  35. Gonfloni S, Iannizzotto V, Maiani E, Bellusci G, Ciccone S and Diederich M.. P53 and Sirt1: Routes of metabolism and genome stability. Biochemical pharmacology. 2014; S0006-2952(14)00524-3. doi: 10.1016/j.bcp.2014.08.034. [Epub ahead of print].

  36. Bergot AS, Ford N, Leggatt GR, Wells JW, Frazer IH and Grimbaldeston MA. HPV16-E7 Expression in Squamous Epithelium Creates a Local Immune Suppressive Environment via CCL2- and CCL5- Mediated Recruitment of Mast Cells. Plos one. 2014; 10(10):e1004466.

  37. Hanahan D and Weinberg A R. The Hallmarks of Cancer. Cell; 2000;100: 57-70.

  38. Koay MHE, Crook M and Stewart CJR. Cyclin D1, E-cadherin and beta-catenin expression in FIGO Stage IA cervical squamous carcinoma: diagnostic value and evidence for epithelial–mesenchymal transition. Histopathology. 2012; 61(6): 1125–1133.

  39. Tan HK1, Moad AI, Tan ML. The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals. Asian Pacific Journal Cancer Prevention. 2014; 15(16):6463-6475.

  40. Ledoa B, Covadonga M, Sánchez CC, de la Peña G, Blanco S, Linder JF, Gómez CD and Lasunción MA. Papel de p38 MAPK en los efectos de la inhibición de la biosíntesis de colesterol en la progresión del ciclo celular en la línea promielocítica humana HL-60. 2008; 20(5): doi: 10.1016/S0214-9168(08)75906-0.

  41. Okinaga T, Ariyoshi W, Akifusa S and Nishihara T. Essential role of JAK/STAT pathway in the induction of cell cycle arrest in macrophages infected with periodontopathic bacterium Aggregatibacter actinomycetemcomitans. Medical microbiology and immunology. 2013; 202(2):167-174.

  42. Klement K and Goodarzi AA. DNA double strand break responses and chromatin alterations within the aging cell. Experimental cell research. Experimental cell research. 2014; S0014-4827(14)00382-6. doi: 10.1016/j.yexcr.2014.09.003. [Epub ahead of print].

  43. Schmitt E, Paquet C, Beauchemin M, and Bertrand. DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. Journal of Zhejiang University. Science. 2007; 8(6):377-97.

  44. Vincent K, Pichler M, Lee GW, Ling H. MicroRNAs, Genomic Instability and Cancer. International journal of molecular sciences. 2014; 15(8):14475-14491.

  45. Hu H and Gatti RA. MicroRNAs: new players in the DNA damage response. Journal of molecular cell biology. 2010; 3(3):151-158.

  46. Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A,Weidhaas JB, Slack FJ. The mir-34 microRNA is required for the DNA damage response in vivo in C. Elegans and in vitro in human breast cancer cells. 2009; 28(25): 2419-2424.

  47. Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene. 2010; 29(7): 937-948.

  48. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, Jackson AL, Carleton MO, Linsley PS, Cleary MA, Chau BN. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Research 2008; 68(24): 10105-10112.

  49. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes and Cancer. 2004; 39(2): 167-169.

  50. Iorio MV, Ferracin M , Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosemberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Research. 2005; 65; (16): 7065-7070.

  51. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka J, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell. 2006; 9(3): 189-198.

  52. Bagnyukova TV, Pogribny IP, Chekhun VF. MicroRNAs in normal and cancer cells: a new class of gene expression regulators. Experimental Oncology. 2006; 28(4): 263-269.




2020     |     www.medigraphic.com